Aim To assess the cost-effectiveness of dapagliflozin in addition to standard care versus
standard care alone in patients with chronic heart failure and reduced ejection fraction …

Background: Empagliflozin is the first medication to demonstrate clinical benefit in patients
with heart failure with preserved ejection fraction, but its cost-effectiveness is unknown. We …

To investigate the effectiveness of multicomponent integrated care on clinical outcomes
among patients with chronic heart failure. We conducted a meta‐analysis of randomized …

Aims We aimed to recruit a representative cohort of women and men with multi-morbid
chronic heart disease as part of a trial testing an innovative, nurse-co-ordinated, multi …

Aims To examine sex-stratified differences in the association of left ventricular ejection
fraction-based heart failure (HF) subtypes and the characteristics and correlates of self …

Advanced chronic kidney disease (CKD) frequently aggravates heart failure (HF). However,
these patients have inherently been excluded from most HF trials. We aim to provide …

Background Frailty is an important predictive measure of mortality and rehospitalisation in
people with heart failure. To date, there are no frailty instruments validated for use in people …

Background The New South Wales (NSW) Heart Failure Snapshot sought to provide a
contemporaneous profile of patients admitted with acute heart failure. We have previously …

Objective Recent studies have reported suboptimal up-titration of heart failure (HF) therapies
in patients with heart failure and a reduced ejection fraction (HFrEF). Here, we report on the …

Background: The impact of different patterns of multimorbidity in heart failure (HF) on health
outcomes is unknown. Objectives: The aim of this study was to test the hypothesis that …